Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,344 result(s) found. Displaying page 1,879 of 2,218.
    «« First « Previous 1875  1876  1877  1878  1879  1880  1881  1882  1883  Next» Last»»
    EudraCT Number: 2020-004851-34 Sponsor Protocol Number: BT008E Start Date*: 2021-04-14
    Sponsor Name:INSIGHTEC
    Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002672-13 Sponsor Protocol Number: CRHACS Start Date*: 2021-03-18
    Sponsor Name:ALMA MATER STUDIORUM UNIVERSITà DI BOLOGNA
    Full Title: CPAP Reduces Hypoxemia After Cardiac Surgery (CRHACS Trial). A randomized controlled trial
    Medical condition: Hypoxemia after cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003127-41 Sponsor Protocol Number: BT009E Start Date*: 2021-05-12
    Sponsor Name:INSIGHTEC
    Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) with Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carbopla...
    Medical condition: Recurrent Glioblastoma (rGBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001503-20 Sponsor Protocol Number: MedOPP150(ATRACTIB) Start Date*: 2021-07-30
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGAT...
    Medical condition: Advanced or metastatic triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005626-29 Sponsor Protocol Number: IRFMN-SARCO-7953 Start Date*: 2021-05-05
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A phase II study on trabectedin in combination with PPARg agonist pioglitazone in patients with round cell myxoid liposarcomas or dedifferentiated G1 and G2 liposarcomas with stable disease after a...
    Medical condition: Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024628 Liposarcomas malignant HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073139 Round cell liposarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073137 Myxoid liposarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001906-41 Sponsor Protocol Number: MRHT_ES-IF_RCT001 Start Date*: 2016-08-08
    Sponsor Name:Royal College of Surgeons in Ireland
    Full Title: A randomised control trial of intra articular injectates in knee osteoarthritis: A comparison of corticosteroid (Methylprednisolone Acetate) and NSAID (Ketorolac tromethamine) injections
    Medical condition: Knee osteoarthritis is the condition of interest. Osteoarthritis is a common musculoskeletal complaint, with an underlying pathogenesis related to bio-mechanical stress loading, resulting in initia...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002076-13 Sponsor Protocol Number: NS-065/NCNP-01-301 Start Date*: 2020-03-02
    Sponsor Name:NS Pharma, Inc.
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) ES (Ongoing) NL (Ongoing) GR (Completed) IT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2019-001500-38 Sponsor Protocol Number: LIN-MD-64-EU-3 Start Date*: 2020-06-15
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of Linaclotide Administered Orally to Children, Ages 6 to 17 Years, With Functional C...
    Medical condition: Functional Constipation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10010774 Constipation PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) EE (Completed) DE (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000540-60 Sponsor Protocol Number: SGNTUC-017 Start Date*: 2020-08-10
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer
    Medical condition: HER2+ Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002633-34 Sponsor Protocol Number: ESK-001-006 Start Date*: 2023-02-07
    Sponsor Name:Alumis Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001517-16 Sponsor Protocol Number: PQGrass306 Start Date*: 2022-09-29
    Sponsor Name:Allergy Therapeutics (UK) Ltd.
    Full Title: A randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of PQ Grass in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass...
    Medical condition: Seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen exposure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003415-19 Sponsor Protocol Number: JM-010CS03 Start Date*: 2018-10-31
    Sponsor Name:Contera Pharma
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study in Parkinson’s Disease Patients With Moderate to Severe Dyskinesia to Assess the Efficacy and Safety/Tolerability of Two Dose Co...
    Medical condition: Parkinson’s Disease Patients With Moderate to Severe Dyskinesia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000176-11 Sponsor Protocol Number: HM-GLP2-201 Start Date*: 2021-12-20
    Sponsor Name:Hanmi Pharmaceutical Co., Ltd.
    Full Title: A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects with Short Bowel Syndrome-associated Intesti...
    Medical condition: Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10049416 Short-bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001144-39 Sponsor Protocol Number: GBMBIBT01 Start Date*: 2008-08-12
    Sponsor Name:Rigshospitalet
    Full Title: A randomized phase II trial with bevacizumab, irinotecan and cerebral radiotherapy versus bevacizumab, temozolomide and cerebral radiotherapy as first line treatment for patients with glioblastoma ...
    Medical condition: This study investigates first line experimental non-surgical therapy in patients with glioblastoma multiforme in good performance status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-004399-16 Sponsor Protocol Number: CHERUB01 Start Date*: 2021-04-28
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial
    Medical condition: chronic cluster headache
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10009698 Cluster headaches LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021407-24 Sponsor Protocol Number: BIBF1120-GBM Start Date*: 2010-11-09
    Sponsor Name:Rigshospitalet
    Full Title: Phase II study of BIBF 1120 in recurrent Glioblastoma multiforme
    Medical condition: Relapsed glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003925-13 Sponsor Protocol Number: CA209-9UP Start Date*: 2018-02-19
    Sponsor Name:Rigshospitalet
    Full Title: A phase II Open Label, two-armed Translational Study of Nivolumab in Combination with Bevacizumab for Recurrent Glioblastoma
    Medical condition: Glioblastoma, recurrent/progressive
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006011-74 Sponsor Protocol Number: BI-Brain-01 Start Date*: 2007-02-01
    Sponsor Name:Rigshospitalet
    Full Title: A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy
    Medical condition: Primary malignant brain tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-001308-35 Sponsor Protocol Number: EB-UGI 01 Start Date*: 2006-05-04
    Sponsor Name:The Finsen Center, Rigshospitalet
    Full Title: A phase II study of erlotinib and bevacizumab in patients with advanced upper gastrointestinal carcinomas, refractory or intolerable to standard systemic therapy
    Medical condition: Histologically or cytologically verified upper gastro-intestinal carcinoma, including carcinomas of the esophagus, cardia, stomac, pancreas, gall bladder, and bile ducts of the following histologic...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001049-42 Sponsor Protocol Number: Start Date*: 2012-07-05
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme
    Medical condition: Recurrent Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1875  1876  1877  1878  1879  1880  1881  1882  1883  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 08:06:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA